Please ensure Javascript is enabled for purposes of website accessibility

2 Popular Robinhood Stocks I Wouldn't Buy With Free Money

By Prosper Junior Bakiny – Aug 25, 2021 at 9:12AM

Key Points

  • Both of the stocks below are vying for a spot in the coronavirus vaccine market.
  • However, both companies' prospects in this market are dim.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Not every stock on the popular trading app is worth owning.

Robinhood Markets is the company behind investing platform Robinhood. Particularly popular among younger generations, Robinhood has received a lot of praise because of its efforts to "democratize finance." Thanks to its app, many who had never invested in stocks before are now actively doing so. Considering the stock market remains one of the best wealth generators for the common person, that is not a bad thing. 

With that said, Robinhood investors aren't perfect, and while the company's list of the 100 most popular stocks on the platform features some excellent picks, others aren't so great. Here are two popular Robinhood stocks I wouldn't buy with free money: Ocugen (OCGN 6.12%) and Inovio Pharmaceuticals (INO 5.70%)

1. Ocugen

Ocugen -- a clinical-stage biotech, meaning it currently has no commercialized products -- is playing catch-up in the coronavirus vaccine market. That's not necessarily a losing strategy, particularly for a company this size; its current market cap only stands at $1.45 billion. There remains some white space in the COVID-19 vaccine market, especially in developing countries and given the advent of newer variants of the disease. 

Doctor vaccinating a patient.

Image source: Getty Images.

If Ocugen earns Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for its candidate and racks up even $1 billion in sales, it would be a major win for the company. However, there are some major issues to consider. First, the company inked a deal to co-develop and co-commercialize its candidate, Covaxin, with India-based Bharat Biotech. While Ocugen will hold commercial rights to the vaccine in the U.S. and Canada (pending approval), it will only keep 45% of the profits generated by Covaxin in these countries.

Second, the prospects for a speedy EUA in the U.S. are all but gone for Covaxin. Per the FDA's recommendation, Ocugen is now likely to file a Biologics License Application, which will take several months longer to be reviewed than an EUA. Third, Covaxin's ability to grind out market share in this competitive space is doubtful. In a phase 3 clinical trial conducted in India that enrolled 25,798 participants, the vaccine candidate proved 77.8% effective against COVID-19. Its efficacy against the rapidly spreading delta variant was 65.2%.

Meanwhile, the vaccines developed by Pfizer, Moderna, and Novavax have all shown overall efficacy of 90% or greater. Could Covaxin's overall efficacy be lower at least in part because its late-stage study was conducted in India, where the delta variant originated? Maybe, but other vaccines, including the one marketed by Johnson & Johnson, have also shown potency against this variant. Putting all of this together and adding the usual risks biotech companies face (including potential unforeseen clinical and regulatory setbacks), Ocugen seems far too risky to invest in at the moment. 

2. Inovio Pharmaceuticals

Inovio Pharmaceuticals is also hoping to enter the COVID-19 market with its candidate, INO-4800. However, the biotech's prospects are even worse than those of Ocugen. Inovio faces at least two major challenges. First, the company is unable to run a phase 3 clinical trial in the U.S. because of concerns regulators raised regarding the proprietary device it uses to administer its vaccine, the Cellectra 2000.

Second, the U.S. government withdrew funding for the phase 3 portion of its phase 2/3 study for INO-4800. As a clinical-stage biotech, Inovio does not generate any product sales, and while it did receive grants last year to help with its coronavirus-related efforts, with several vaccines now widely available, the company will have a hard time attracting additional third-party grants.

So is INO-4800 destined to remain in Inovio's late-stage pipeline forever? Not necessarily. The company plans on running a phase 3 clinical trial in Asia and South America in collaboration with Advaccine Biopharmaceuticals Suzhou. The study, which is supposed to kick off before the end of the summer, will test the safety and efficacy of two doses of the vaccine candidate administered one month apart. In theory, Inovio could also manage to generate decent sales from INO-4800 given the advent of newer variants of the virus. But by the time the phase 3 study is complete, there is no telling how much of the coronavirus vaccine market will be left up for grabs.

Time isn't on Inovio's side, and betting that the company's master plan will come to fruition seems speculative. In short, it'd be best to stay away from this company -- at least for now.

Prosper Junior Bakiny owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson and Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
$1.56 (6.12%) $0.09
Johnson & Johnson Stock Quote
Johnson & Johnson
$178.00 (1.08%) $1.91
Pfizer Stock Quote
$50.13 (1.29%) $0.64
Inovio Pharmaceuticals Stock Quote
Inovio Pharmaceuticals
$2.04 (5.70%) $0.11
Novavax Stock Quote
$16.49 (-2.02%) $0.34
Moderna Stock Quote
$175.91 (1.59%) $2.76
Robinhood Markets Stock Quote
Robinhood Markets
$9.59 (4.47%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.